Klopidex

Clopidogrel, the active ingredient in Klopidex, is an antiplatelet agent presented as an oral formulation for systemic use. It is employed to reduce the risk of atherothrombotic events in patients with recent myocardial infarction, acute coronary syndrome, ischemic stroke, or peripheral arterial disease.

GNH USA supplies Klopidex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klopidex (clopidogrel) is used to inhibit platelet aggregation in several cardiovascular and cerebrovascular conditions.

- Recent myocardial infarction: lowers the risk of recurrent heart attacks and related complications. - Acute coronary syndrome: helps prevent further clot formation during unstable angina or non‑ST elevation myocardial infarction. - Ischemic stroke prevention: reduces the chance of a new stroke in patients with a prior ischemic event. - Peripheral arterial disease: diminishes the likelihood of limb‑related thrombotic events.

Adverse reactions to clopidogrel can vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: occasional loose stools. - Nausea: transient stomach upset. - Bruising: easy bruising at sites of minor trauma. - Rash: mild skin irritation or erythema. - Dyspepsia: occasional indigestion.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Thrombotic thrombocytopenic purpura (TTP): rare but life‑threatening. - Neutropenia: marked reduction in white blood cells. - Hepatic failure: abnormal liver function tests. - Allergic reactions: anaphylaxis or angioedema. - Hematologic abnormalities: aplastic anemia.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Bleeding risk assessment: evaluate history of hemorrhage or active ulcers. - Platelet monitoring: check counts in patients with hematologic disorders. - Concomitant NSAIDs: avoid or use with caution due to increased bleeding. - Renal impairment: adjust therapy in severe kidney disease. - Surgical procedures: discontinue appropriately before elective surgery. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Clopidogrel may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): reduce antiplatelet effect. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs): elevate hemorrhagic potential. - Proton pump inhibitors with high CYP2C19 activity: may diminish efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma levels. - Other antiplatelet agents (e.g., aspirin): assess cumulative bleeding risk. - Statins metabolized by CYP3A4 (e.g., atorvastatin): monitor for adverse effects. - Herbal supplements (e.g., ginkgo biloba): possible additive antithrombotic effect. - Diabetes medications (e.g., sulfonylureas): monitor glycemic control if bleeding occurs.